Robert Marcus, MA, FRCP, FRCPath from Kings’ College Hospital, London, UK discusses his lymphoma highlights from this year’s 2017 British Society for Hematology (BSH) Annual Scientific Meeting in Brighton, UK. Over the years there have been major advances in the treatment options for chronic lymphocytic leukemia (CLL). The introduction of new drugs such as ibrutinib and venetoclax are slowly shifting the focus from chemotherapy to more biologically based treatments. The prospect for both low-grade and high-grade lymphoma seem disappointing and there are no major improvements in terms of treatment for either of these types of lymphoma. On the other hand, Dr Marcus says that the research into new biological agents for mantle cell lymphoma look promising and there are indications of good progression-free survival with ibrutinib therapy. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.